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Abstract Diabetic neuropathy (DN) is characterized as
Hyperglycemia activates thdisturbed nerve conduction and
progressive chronic pain. Inflammatory mediators, partic-
ularly cytokines, have a determinant role in the
pathogenesis of neuropathic pain. The activity of adenosine
monophosphate protein kinase (AMPK), an energy charge
sensor with neuroprotective properties, is decreased in
diabetes. It has been reported that activation of AMPK
reduces the systemic inflammation through inhibition of
cytokines. In this study, we aimed to investigate the
probable protective effects of AMPK on DN in a rat of
diabetes. DN was induced by injection of streptozotocin
(65 mg/kg, i.p.). Motor nerve conduction velocities
(MNCV) of the sciatic nerve, as an electrophysiological
marker for peripheral nerve damage, were measured.
Plasma levels of IL-6, TNF-a, CRP were assessed as
relevant markers for inflammatory response. Also, the
expression of phosphorylated AMPK (p-AMPK) and non-
phosphorylated (non-p-AMPK) was evaluated by western
blotting in the dorsal root ganglia. Histopathological
assessment was performed to determine the extent of nerve
damage in sciatic nerve. Our findings showed that activa-
tion of AMPK by metformin (300 mg/kg) significantly
increased the MNCV and reduced the levels of inflamma-
tory cytokines. In addition, we showed that administration
of metformin increased the expression of p-AMPK as well
as decline in the level of non p-AMPK. Our results
demonstrated that co-administration of dorsomorphin with
metformin reversed the beneficial effects of metformin. In
conclusion, the results of this study demonstrated that the
activation of AMPK signaling pathway in diabetic neu-
ropathy might be associated with the anti-inflammatory
response.
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Introduction
In diabetic neuropathy (DN), demyelination and neuron
damage lead to disturbance in nerve conduction (Tracy and
Dyck 2008). Nerve conduction study is a noninvasive
procedure to measure the nerve function which clinically
used for evaluation of neuropathy in patients (Vinik et al.
2006). Reduce motor nerve conduction velocity (MNCV)
is described as an indicator of diabetic neuropathy (Yorek
et al. 1993).
Previous studies have indicated that tumour necrosis
factor-a (TNF-a) plays a key role in the pathophysiology
of chronic pain (Zhang et al. 2013). In this regard, it has
been shown that levels of inflammatory cytokines
increased in the blood of diabetic patients (Gonzalez-Cle-
mente et al. 2005; Uceyler et al. 2007). It is well accepted
that the levels of C-reactive protein (CRP) as well as
interleukin (IL)-6 increased in the circulation of patients
with diabetes which are directly associated with diabetic
neuropathy (Hills and Brunskill 2009). Previous studies
demonstrated that metformin was able to prevent from the
development of neuropathy in diabetic patients (Knowler
et al. 2002; Valk et al. 2002).
Ample evidence has determined that activation of ade-
nosine monophosphate protein kinase (AMPK) is the main
mechanism of action of metformin in the correction of
metabolic syndrome in diabetes (Zhou et al. 2001). Studies
have shown that AMPK activity reduced in diabetes (Lee
et al. 2007). It is well established that antihyperglycemic
effects of metformin are mediated through AMPK stimu-
lation (Cho et al. 2015). AMPK activation decreases the
blood glucose level through attenuation of glucose uptake
(McGee et al. 2008) and inhibition of gluconeogenesis
(Novikova et al. 2015). However, it is shown that met-
formin diminished gluconeogenesis in an AMPK-
independent pathway in a mouse model of diabetes (Foretz
et al. 2010).
Steinberg et al. showed that inflammatory cytokines via
increase the expression of protein phosphatase 2C (PP2C),
an inhibitor of AMPK suppressed the activity of AMPK
(Steinberg et al. 2006). It is shown that metformin, an
AMPK activator, reduced the systemic inflammation in
mild metabolic syndrome (Akbar 2003). Dorsomorphin
(Compound C), an AMPK inhibitor, is a known tool for
investigating the role of AMPK in biological processes
(Novikova et al. 2015; Liu et al. 2014; Kimura et al.
2014).
Previous studies demonstrated the positive effects of
metformin in diabetic neuropathy; however, the exact
mechanisms of this agent are unclear. In this study, we
aimed to examine the anti-inflammatory and protective
effects of activation of AMPK signaling pathway using
metformin on the diabetes-induced neuropathy consider-
ing blood glucose level, inflammatory markers and
MNCV in a rat diabetic model. We demonstrated that
AMPK signaling loop at least partially modulated the
anti-inflammatory and protective effects of metformin in
the DN.
Materials and methods
Materials
Chemicals used in this study consisted of: Streptozotocin
(Sigma-Aldrich, USA), metformin and dorsomorphin
dihydrochloride (Compound C) (Tocris Bioscience, USA),
CRP ELISA kit, IL-6 ELISA kits and TNF-a ELISA kit
(Abcam, USA), antibody Thr_172 and PP2C_a (Santa
Cruz, CA).
Methods
Subjects and study design
Eighty male Wistar rats (obtained from Department of
Pharmacology, School of Medical, Tehran University of
Medical Sciences, Tehran, Iran) weighing 210 ± 10 g
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were used. In order to induction of diabetes, a single
injection of streptozotocin (STZ) at the dose of 65 mg/
kg, intraperitoneally (i.p.) was used. 24 h before
administration of STZ, animals were deprived of food.
The Ethics Committee approved all the ethical guideli-
nes of experimental pain in awaked animals
(Zimmermann 1983).
Animals randomly assigned into eight groups as follows
(n = 10 in each group): (1) saline; (2) STZ; (3) metformin
(300 mg/kg); (4) STZ ? metformin (300 mg/kg); (5) dor-
somorphin (0.2 mg/kg); (6) STZ ? dorsomorphin (0.2 mg/
kg); (7) metformin (300 mg/kg) ? dorsomorphin (0.2 mg/
kg); (8) STZ ? metformin (300 mg/kg) ? dorsomorphin
(0.2 mg/kg).
Blood samples were taken from the tail, and glucose
levels were measured 48 h after STZ administration.
Blood glucose C400 mg/dl was considered as diabetic.
We wanted to activate the AMPK with an effective dose
of metformin. So based on the previous studies, we
picked up the dose of 300 mg/kg (Wang et al. 2009;
Zhuo et al. 2013). Metformin (AMPK activator) was
used in 1 ml of drinking water directly conducted into
the stomach by oral gavage, and dorsomorphin (AMPK
inhibitor) was used as i.p. injection from 3 days after
induction of diabetes until the end of the study. The
blood glucose levels were measured using glucometer
(Optium Plus, Abbott Diabetes Care, UK) on 7 days
before induction of diabetes and 4, 18, 32 and 45 days
after induction of diabetes. We selected the 7th day
before induction of DN to take blood samples to mini-
mize handling effects and also diminish stress-induced
inflammatory reactions.
Electrophysiological experiments
MNCV was determined using a non-invasive procedure in
the sciatic-posterior tibial conducting system in a temper-
ature-controlled environment according to the criteria
described by Hasegawa et al. (Hasegawa et al. 2006).
Motor nerve studies were performed on day 7 before and
days 4, 18, 32 and 45 after induction of diabetes using
electrophysiological experiments. Briefly, rats were anes-
thetized with pentobarbital (70 mg/kg), and the body
temperature was maintained at 37 C, followed by stimu-
lation of the sciatic nerve proximal to the sciatic notch and
distal to the knee using bipolar electrodes of a Neu-
ropackREMG machine (Nihon Kohden, Japan). The action
potential of the muscle was recorded from the ankle using
unipolar pin electrodes. MNCV was calculated in meters
per second as the ratio of the distance in millimeters
between both sites of stimulation divided by the difference
between the proximal and distal latencies measured in
milliseconds.
Enzyme-linked immunosorbent assays (ELISA)
Blood samples were centrifuged at 3000g for 10 min to
separate the serum. Serum samples were stored at -70 C
until the measurement of inflammatory markers including
TNF-a, CRP, and IL-6 using ELISA kit according to the
manufacturer’s guideline (Saeedi Saravi et al. 2016).
Histological and morphological studies
45 days after diabetes induction, the sciatic nervewas isolated
and fixed in 10 % formalin. Then, samples were cut into
segments of 5-lm sections using microtome and stained with
hematoxylin and eosin. A pathologist, blinded to the study,
analyzed the slides using previously established scales for
perineural inflammation as follows: 0 = no inflammation,
1 = small focal areas of mild edema and/or cellular infiltrate,
2 = locally extensive areas of moderate edema/cellular
infiltrate, 3 = diffuse areas of moderate to marked
edema/cellular infiltrate. Evaluation of nerve damage per-
formed as the following: 0 = no lesions, 1 = 0–2 % of the
fibers with lesions in axons or myelin, 2 = 2–5 % with
lesions, 3 =[5 % with lesions (Brummett et al. 2009).
Western blot procedure
Western blotting was performed according to the protocol
described by Eslami et al. (Eslami and Lujan 2010).
Briefly, 45 days after diabetes induction, the dorsal root
ganglia (DRG) was isolated, and the protein was separated
by gel electrophoresis (10 % gel) and transferred to
polyvinylidene fluoridated (PVDF) membranes. The PVDF
membranes were incubated with primary antibody Thr-172
(phosphorylated AMPK) and PP2C-a (non-phosphorylated
AMPK). Subsequently, the membranes were treated with
the horseradish peroxidase-conjugated secondary antibod-
ies. Immune complexes were visualized using ECL plus
detection reagents.
Statistical analysis
All data presented as Mean ± SEM. One-way ANOVA
analysis followed by Tukey’s post hoc test was used for
evaluation of blood glucose levels, inflammatory markers,
MNCV and Western blotting results. One-way ANOVA
analysis followed by Dunnett post hoc test was used for data
analysis of histopathological findings. p values less than 0.05
were considered as statistically significant. The sample size
was calculated by power calculations using G power soft-
ware (ver.3.1.7, Franz Faul, Universitat Kiel, Germany). We
set a error at 0.05 and power (1 - b) at 0.8 and the required
total sample size per group was calculated as 8–10 animals.
Accordingly, we selected ten rats in each group.
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Results
Metformin decreased blood glucose levels
One-way ANOVA analysis showed that there are signifi-
cant differences between experimental groups in blood
glucose levels on days 4 [F(7, 72) = 161.1, p\ 0.001], 18
[F(7, 72) = 172.2, p\ 0.001], 32 [F(7, 72) = 310.1,
p\ 0.001] and 45 [F(7, 72) = 233, p\ 0.001].
As shown in Fig. 1, the blood glucose concentrations in
STZ (diabetic) groups were significantly increased in
comparison with saline (control) groups on days 4, 18, 32
and 45 after diabetes induction. Post hoc test analysis
demonstrated that administration of metformin signifi-
cantly decreased blood glucose levels on days 4, 18, 32 and
45 after induction of diabetes. In addition, administration
of dorsomorphin did not decrease blood glucose concen-
trations in STZ groups. Furthermore, administration of
dorsomorphin reversed the effects of metformin on the
glucose levels on days 4, 18, 32 and 45 after induction of
diabetes. Results showed that there was no significant
difference between groups in day 7 before induction of
diabetes.
Metformin restored MNCV
One-way ANOVA analysis showed that there are signifi-
cant differences between experimental groups in MNCV on
days 18 [F(7, 72) = 36.52, p\ 0.001], 32 [F(7, 72) =
245.7, p\ 0.001] and 45 [F(7, 72) = 676.5, p\ 0.001].
As shown in Fig. 2, there is no significant difference
between the groups in day 7 before diabetes induction as
well as the 4th day after induction of diabetes in the
MNCV (Images of MNCV have been shown as supple-
mentary data). MNCV was significantly decreased in
diabetic rats compared to control rats (saline) on days 18,
32 and 45 after induction of diabetes. Moreover, our results
showed that administration of metformin increased MNCV
in a significant manner in days 18, 32 and 45 after induc-
tion of diabetes in comparison with STZ group (Fig. 2).
Metformin reduced the level of CRP
One-way ANOVA analysis showed that there are signifi-
cant differences between experimental groups in CRP
levels on days 18 [F(7, 72) = 4.518, p\ 0.0025], 32 [F(7,
72) = 64.94, p\ 0.001] and 45 [F(7, 72) = 187,
p\ 0.001].
Figure 3 shows the results of CRP assessment. As
shown, the level of CRP significantly increased in the
serum of diabetic animals as compared to control (saline)
groups on days 45 after induction of diabetes in rats.
Results showed that metformin reduced the concentration
of CRP in the serum of diabetic rats on days 18, 32 and 45
after induction of diabetes when compared to STZ group.
However, administrations of dorsomorphin alone or with
metformin have not effected on CRP levels. Metformin
failed to change the level of CRP on day 4 after induction
of diabetes as well as day 7 before administration of STZ.
Metformin reduced the level of IL-6
One-way ANOVA analysis showed that there are signifi-
cant differences between experimental groups in levels of
IL-6 on days 18 [F(7, 72) = 39.73, p\ 0.001], 32 [F(7,
72) = 21.52, p\ 0.001] and 45 [F(7, 72) = 51.79,
p\ 0.001].
Analysis showed that the level of IL-6 significantly
increased in diabetic rats in comparison with control ones
on days 18, 32 and 45 after induction of diabetes. Post-test
analysis demonstrated that unlike days 7 before and 4 after
induction of diabetes, metformin on days 18, 32 and 45
after STZ administration reduced the levels of IL-6 when
compared to STZ rats. Furthermore, our findings showed
that co-administration of metformin with dorsomorphin in
day 18 after diabetes induction decreased the IL-6 levels in
comparison with STZ group (Fig. 4).
Metformin reduced the level of TNF-a
One-way ANOVA analysis showed that there are signifi-
cant differences between experimental groups in levels of
TNF-a on days 18 [F(7, 72) = 19.1, p\ 0.001], 32 [F(7,
72) = 88.43, p\ 0.001] and 45 [F(7, 72) = 198.8,
p\ 0.001].
ANOVA analysis showed that the level of TNF-a sig-
nificantly increased in diabetic rats in comparison with
control (saline) animals on days 18, 32 and 45 after STZ
administration. Post hoc test analysis showed that unlike
days 7 before and 4 after administration of STZ, metformin
on days 18, 32 and 45 after STZ administration signifi-
cantly reduced the levels of TNF-a in serum samples when
compared to diabetic groups (Fig. 5). In addition, co-ad-
ministration of metformin with dorsomorphin on day 18
after diabetes induction significantly decreased TNF-a in
comparison with STZ group.
Activation of AMPK decreases the perineural
inflammation
Histological and morphological evaluations on sciatic
nerve are shown in Fig. 6. Our findings showed that there
are no signs of inflammation or morphological changes in
the sciatic nerve among groups in control (saline) animals.
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Moreover, histopathological observations showed that
there was extensive perineural inflammation around the
sciatic nerve in STZ, dorsomorphin as well as metformin
plus dorsomorphin in diabetic groups (score = 3). Also,
the histopathological study demonstrated a low level of
inflammation ratio around the sciatic nerve in diabetic rats
treated with metformin (score = 1). Moreover, nerve
damage was not observed in sciatic nerve of all groups.
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AMPK on blood glucose levels.
Data were expressed as
mean ± SEM and analyzed
with one-way ANOVA and
Tukey’s post hoc test (n = 10).
STZ considered as diabetic
group. Saline considered as
control group. ***p\ 0.001
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###p\ 0.001 compared to STZ
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Metformin increased p-AMPK in DRG
To evaluate the expression of AMPK in phosphory-
lated and non-phosphorylated forms in DRG samples,
western blotting was used. Western blotting experi-
ment showed that the level of phosphorylated AMPK
(Thr-172) increased in diabetic group treated with
metformin when compared to the diabetic group.
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Results showed that levels of non-phosphorylated
AMPK (PP2C_a) increased in STZ (diabetic) group.
Additionally, the level of PP2C_a increased in dia-
betic rats treated with metformin plus dorsomorphin
(Fig. 7).
Discussion
In the current study, diabetes was induced by the admin-
istration of STZ. Using metformin, an AMPK activator,
and dorsomorphin, an AMPK inhibitor we evaluated the
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protective effects of AMPK signaling pathway in the dia-
betic neuropathy. We showed that the activation of AMPK
significantly increased the MNCV and decreased the levels
of inflammatory parameters such as TNF-a, IL-6, and CRP
in diabetic rats. Administration of metformin notably
decreased glucose levels when compared to untreated
diabetic rats. Our results showed that treatment with dor-
somorphin did not decrease blood glucose levels in diabetic
rats, and also co-administration of dorsomorphin with
metformin reversed the beneficial effects of metformin on
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blood glucose concentration, inflammatory cytokines, and
MNCV. Furthermore, we evaluated the expression of
AMPK in phosphorylated (p-AMPK) and non-phosphory-
lated forms in DRG samples. Findings demonstrated that
metformin increased the level of p-AMPK which was
decreased in diabetes. These results were in agreement with
our histological observations.
It is well established that hyperglycemia is associated
with over-production of inflammatory cytokines, nerve
conduction impairment as well as mitochondrial
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Fig. 5 Effect of activation of
AMPK on TNF_a. Data were
expressed as mean ± SEM and
analyzed with one-way
ANOVA and Tukey’s post hoc
test (n = 10). STZ considered
as diabetic group. Saline
considered as control group.
***p\ 0.001 compared to
control group, #p\ 0.5 and
##p\ 0.01 compared to STZ
group. STZ streptozotocin, MET
metformin, DORS
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dysfunction which consequently lead to the damage of
sensory neurons in DRG of the spinal cord (Bordet et al.
2008; Leinninger et al. 2006). Streptozotocin is a selective
agent used to destroy the islets of Langerhans and employ
to induce experimental DN in animal models (Jin et al.
2009). The beneficial effects of metformin (AMPK acti-
vator) are mediated through action on the hepatocytes and
muscle cells, as well as reduced glucose production and
increased glucose uptake (Cheng et al. 2006). Dorsomor-
phin is an AMPK inhibitor which reverses the beneficial
effects of AMPK signaling pathway on the glucose levels
(Kimura et al. 2014).
Ample evidence reported that metformin via activation
of AMPK decreases the blood glucose levels in diabetes
(Zakikhani et al. 2008). Metformin acts as a neuroprotec-
tive agent. In this regard, it has been shown that metformin
Fig. 6 a Histological and morphological studies in sciatic nerve at
45 days after diabetes induction. In untreated diabetic rats (B), the
sciatic nerve has diffuse areas of moderate to marked edema/cellular
infiltrate. In the metformin-treated diabetic rats (D), the finding is
small focal areas of mild edema and/or cellular infiltrate. In the
dorsomorphin-treated diabetic rats (F) and metformin plus dorsomor-
phin-treated diabetic rats (H), the sciatic nerves has diffuse areas of
moderate to marked edema/cellular infiltrate. b Scoring of sciatic
nerves for the presence of inflammation. A saline, B STZ, C met-
formin, D STZ ? metformin, E dorsomorphin, F STZ ?
dorsomorphin, G metformin ? dorsomorphin, H STZ ? met-
formin ? dorsomorphin. #p\ 0.5, ##p\ 0.01 and ###p\ 0.01
compared to STZ group
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in neurodegenerative diseases possessed neuroprotective
effects (Correia et al. 2008; Ullah et al. 2012).
Previous studies have determined that the activity of
AMPK signaling cascade decreased in diabetes (Roy
Chowdhury et al. 2012). Clinical studies have shown that
there is an indirect association between the activity of
AMPK pathway with the incidence of neuropathy in dia-
betic patients (Gerich et al. 2005). It is documented that the
activation of AMPK signaling pathway ameliorated the
inflammatory reactions in diabetes (Gaskin et al. 2007; Ido
et al. 2002). Hyperglycemia activates the NF-jB signaling
pathway, subsequently leading to the production of
inflammatory mediators such as IL-6, CRP, and TNF-a
resulting in nerve damage and development of neuropathy
(Takeuchi et al. 2010; Wada and Yagihashi 2005). In line
with aforementioned studies, our results showed that
inflammatory reaction decreased the following adminis-
tration of metformin in which levels of IL-6, CRP and
TNF-a decreased when compared to the untreated diabetic
rats.
Several lines of evidence have shown that diabetic
patients have electrophysiological conduction abnormali-
ties indicating peripheral neuropathy (Zangiabadi et al.
2007). In this context, it is determined that progressive
slowing of motor nerve conduction velocity (MNCV) is an
important complication related to the neuropathy (Coste
et al. 2004). In agreement with previously published study
demonstrated that diabetes led to decrease in conduction
speed of sciatic nerve we showed that MNCV decreased in
diabetic rats which significantly reversed following met-
formin treatment (Coste et al. 2004).
According to previous researches, metformin repaired
sciatic nerve degeneration in diabetic rats. Pathomorpho-
logical assessment indicated that metformin regenerated
sciatic nerve damage consequent of diabetes (Ma et al.
2015). In the current study, we observed that the activation
of AMPK signaling pathway using metformin notably
improved histopathological alterations in the DRG samples
of diabetic rats.
It is well accepted that protein phosphatase 2C (PP2C) is
a dephosphorylate enzyme which inactivates p-AMPK
(Wang and Unger 2005; Wu et al. 2007). Considering
phosphorylation form of AMPK is the active form which is
reduced in diabetes, agents capable of decreasing the PP2C
has potential positive effect in diabetes. Our western
blotting finding showed that metformin significantly
increased the expression of p-AMPK as well as decreased
the expression of PP2C in DRG samples of diabetic rats.
Previous studies have been shown gender differences in
pain sensitivity in rodents. Different response to painful
stimuli in male and female rats attributed to biological
systems and physiological factors such as sex hormones
Fig. 7 a Effects of treated with or without metformin (MET) or
dorsomorphin (DORS) alone, or MET plus DORS at indicated doses
on the levels of phosphorylated (Thr172) and non-phosphorylated
(PP2C-a) activity of AMPK in dorsal root ganglia of control and
experimental rats. b Graphical representation of data from Western
blotting analysis. A saline, B STZ, Cmetformin, D STZ ? metformin,
E dorsomorphin, F STZ ? dorsomorphin, G metformin ? dorsomor-
phin, H STZ ? metformin ? dorsomorphin. #p\ 0.5, ##p\ 0.01
and ###p\ 0.01 compared to STZ group
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and pathway of brain l-receptors activation (Fillingim and
Maixner 1995; Wiesenfeld-Hallin 2005). Boyer et al.
showed that male rats exhibited greater analgesia in
response to morphine application into rostral ventromedial
medulla (Boyer et al. 1998). Considering the influence of
hormonal and genetic difference between female rats in
pain perception, in this study we used only male rats. The
authors suggested that additional study may be worthwhile
to perform in female rat.
Conclusion
In conclusion, results of the present work showed that anti-
inflammatory effects of AMPK signaling pathway
improved the complications of diabetes in experimental
diabetes. Our results showed that activation of AMPK
signaling decreased glucose levels, attenuated inflamma-
tory markers (such as IL-6, CRP, and TNF-a), increased
MNCV of the sciatic nerve and also improved
histopathological scores of sciatic nerves.
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